Brief: Abbvie Completes Acquisition Of Immunogen

ImmunoGen

12/02/2024 13:14

Feb 12 (Reuters) - Abbvie Inc  ABBV.N :
    * ABBVIE COMPLETES ACQUISITION OF IMMUNOGEN
    * ABBVIE REAFFIRMS PREVIOUSLY ISSUED 2024 FULL-YEAR ADJUSTED
DILUTED EPS GUIDANCE RANGE OF $11.05-$11.25
    * UPDATES PREVIOUSLY ISSUED 2024 FIRST-QUARTER ADJUSTED
DILUTED
EPS GUIDANCE RANGE FROM $2.30-$2.34 TO $2.26-$2.30
    * FIRST-QUARTER ADJUSTED DILUTED EPS NOW INCLUDES A $0.04
PER
SHARE DILUTIVE IMPACT RELATED TO IMMUNOGEN ACQUISITION
    * ABBVIE- 2024 ADJUSTED EPS GUIDANCE INCLUDES $0.42 PER
SHARE
DILUTIVE IMPACT RELATED TO COMPLETED IMMUNOGEN
ACQUISITION,PENDING CEREVEL THERAPEUTICS ACQUISITION
    * Q1 EARNINGS PER SHARE VIEW $2.35 -- LSEG IBES DATA
    * FY2024 EARNINGS PER SHARE VIEW $11.19 -- LSEG IBES DATA

Source text for Eikon:  ID:nPn9yB9J4a 
Further company coverage:  ABBV.N 

 ((Reuters.Briefs@thomsonreuters.com;))